Holen Sie sich die Stockscreener-App
2.96
0.67%
-0.02
Handel nachbörslich:
3.00
0.04
+1.35%
Schlusskurs vom Vortag:
$2.98
Offen:
$2.95
24-Stunden-Volumen:
3.72M
Relative Volume:
3.25
Marktkapitalisierung:
$487.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-10.57
EPS:
-0.28
Netto-Cashflow:
$-51.36M
1W Leistung:
-27.27%
1M Leistung:
-21.28%
6M Leistung:
-33.93%
1J Leistung:
-20.64%
1-Tages-Spanne:
$2.815
$3.00
1-Wochen-Bereich:
$2.815
$4.295
52-Wochen-Spanne:
$2.815
$5.70
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SVRA | 2.96 | 487.22M | 0 | -54.70M | -51.36M | -0.28 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - GuruFocus.com
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade - MarketBeat
Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara (SVRA) to Present at Jefferies and Piper Sandler Healthcare Conferences | SVRA Stock News - StockTitan
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Fast-Tracks MOLBREEVI FDA Filing Despite Widening Q3 Losses, $219M Cash Runway | SVRA Stock News - StockTitan
Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV - Yahoo Canada Finance
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
Savara Inc. Grants Inducement Awards to New Chief Commercial Officer - MSN
Piper Sandler keeps Overweight rating on Savara shares - Investing.com
FY2025 EPS Estimates for Savara Inc (NASDAQ:SVRA) Reduced by HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Trading Down 3.5% - MarketBeat
Savara maintains buy stock rating on aPAP drug potential By Investing.com - Investing.com Australia
Savara maintains buy stock rating on aPAP drug potential - Investing.com
JMP Securities Reiterates “Market Outperform” Rating for Savara (NASDAQ:SVRA) - Defense World
Will Savara Inc (SVRA) beat or miss earnings estimates this quarter? - US Post News
Metric Analysis: Savara Inc (SVRA)’s Key Ratios in the Limelight - The Dwinnex
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):